Timing of new black box warnings and withdrawals for prescription medications.

@article{Lasser2002TimingON,
  title={Timing of new black box warnings and withdrawals for prescription medications.},
  author={Karen E Lasser and Paul D. Allen and Steffie Woolhandler and David Himmelstein and Sidney M. Wolfe and David H. Bor},
  journal={JAMA},
  year={2002},
  volume={287 17},
  pages={
          2215-20
        }
}
CONTEXT Recently approved drugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no recent studies have examined how frequently postmarketing surveillance identifies important ADRs. OBJECTIVE To determine the frequency and timing of discovery of new ADRs described in black box warnings or necessitating withdrawal of the drug from the market. DESIGN AND SETTING Examination of the Physicians' Desk Reference for all new chemical entities… 

Tables from this paper

Safety of newly approved drugs: implications for prescribing.
TLDR
The timing and nature of the black box warnings added to labeling, as reflected in the Physicians’ Desk Reference, and of removal of drugs from the market are examined to address the question of whether clinicians should hesitate to prescribe new drugs that may have unrecognized adverse drug reactions (ADRs).
How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
  • J. Lexchin
  • Medicine, Political Science
    Open medicine : a peer-reviewed, independent, open-access journal
  • 2014
TLDR
The finding of no difference in the percentage of drugs approved in the four 5-year periods that were eventually withdrawn is the lack of any change in the rigour of the premarket evaluation system and the postmarket surveillance systems.
An analysis of legal warnings after drug approval in Thailand.
FDA boxed warnings: how to prescribe drugs safely.
TLDR
Boxed warnings have been issued recently for oral sodium phosphate bowel preparations, fluoroquinolone antibiotics, and salmeterol, despite these highly publicized warnings, all of these medications remain viable treatment options with appropriate patient selection.
Black box warnings-implications in practice.
Adherence to black box warnings for prescription medications in outpatients.
TLDR
In an observational study of 51 outpatient practices using an electronic health record, the frequency with which patients received prescriptions in violation of black box warnings for drug-drug, drug-laboratory, and/or drug-disease interactions was measured.
Black-box warning and psychiatric drugs: a problem or a solution?
TLDR
The aim of this review was to search for the causes of warning for psychiatric medications and how to remedy this problem, and to determine the effect of these warnings on practice with regard to current drug regulations in Egypt.
The "black box" warning and allergy drugs.
  • D. Aaronson
  • Medicine
    The Journal of allergy and clinical immunology
  • 2006
Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
  • J. Lexchin
  • Medicine, Political Science
    BMJ Open
  • 2014
TLDR
There was no difference in postmarket regulatory safety action between traditional medications and biologics and no difference between drugs with significant therapeutic benefits and those without.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Black box warnings in prescription drug labeling: results of a survey of 206 drugs.
TLDR
The authors surveyed 206 black box warnings in package inserts in an attempt to determine both the kind of information the agency sought to impart to the physician and the types of human studies relied upon by the agency.
Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety
TLDR
Since drugs discontinued while a safety question existed represent only 2% of the new chemical entities introduced, it appears that drugs that reach the market under the prevailing regulatory systems are seldom associated with unacceptable toxicity.
Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.
TLDR
Methods to evaluate ADRs using data from clinical trials, medical records, and computerized databases of medication users and nonusers must be developed to complement spontaneous reporting systems.
Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference.
TLDR
Although the PDR is the drug reference most used by physicians, it does not reflect the lowest initial doses that are recommended by the JNC VI for many of the most prescribed antihypertensive drugs.
The Impact of a Direct-to-Consumer Prescription Medication Advertising Campaign on New Prescription Volume
TLDR
Assessment of the relationship between existence of an informational DTCA campaign for a newly-marketed prescription medication and new prescription volume suggested that D TCA was effective in generating new prescriptions while the campaign was in effect, with residual but declining effects after discontinuation.
How should efficacy be evaluated in randomized clinical trials of treatments for depression?
  • M. Thase
  • Psychology
    The Journal of clinical psychiatry
  • 1999
TLDR
The process of conducting the clinical trials that support a New Drug Application is described, issues in evaluating efficacy are discussed, and suggestions for modifying and improving the drug development process are offered so that clinicians can better judge new drugs.
Modernizing the FDA: an incremental revolution.
TLDR
The agency's role is defined by a growing and increasingly complex set of statutes, which reflect Congress's desires to prevent product hazards and to expedite FDA review and approval of promising new medical technologies.
...
1
2
3
...